Iovance Biotherapeutics Inc Dossier - Source-backed chat

Iovance Biotherapeutics Inc

IOVANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.78

Intrinsic Value $7.23median of 2 methodsbased on filings through 30 Jun 2026

Market Price $14.23Price as of 1 Oct 2026

OvervaluedIntrinsic value is 49% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $6.4B

Enterprise Value $6.3B

Shares Outstanding 463.1M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Iovance Biotherapeutics is successfully transitioning from a clinical-stage biotech to a commercial-stage leader in solid tumor cell therapy. The launch of Amtagvi (lifileucel), the first FDA-approved T-cell therapy for a solid tumor (advanced melanoma), is driving rapid revenue growth, with Q1 2026 product sales reaching $71.4 million (up 45% YoY). Despite near-term unprofitability and facility maintenance headwinds in Q1, the company's recent manufacturing expansion at the iCTC, a solid cash runway extending into 2028, and international regulatory milestones (such as the June 2026 Australian approval) support a highly positive growth trajectory.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$9.22

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Commercial execution slows due to logistical bottlenecks at ATCs or manufacturing setbacks at the iCTC. High cash burn persists, requiring dilutive equity raises before reaching profitability, despite the current runway into 2028. Regulatory delays in Europe or competitive pressures from alternative cell therapies limit the peak market penetration of Amtagvi.

Base CaseCentral scenario

Amtagvi adoption continues to accelerate across activated ATCs in the U.S., meeting the FY2026 revenue guidance of $350M to $370M. Manufacturing efficiencies and the recent iCTC expansion drive gross margin expansion above 50% in the second half of 2026. International launches in Australia and regulatory progress in Switzerland provide mid-term catalysts, while late-stage trials in NSCLC and endometrial cancer expand the addressable market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage as the only FDA-approved TIL therapy for solid tumors (advanced melanoma).
Rapidly scaling commercial revenues with strong Q1 2026 performance ($71.4M, +45% YoY) and robust Q2 guidance ($86M-$88M).
Strong balance sheet with $319.4M in cash and investments, providing an operational runway into 2028.
Expanding pipeline with positive clinical signals in endometrial cancer (40% ORR) and NSCLC.

Key Investment Risks

High operational complexity and logistical sensitivity of autologous cell therapy manufacturing.
Near-term unprofitability and risk of future capital dilution if commercial ramp-up is delayed.
Regulatory hurdles, as evidenced by the procedural withdrawal of the UK marketing application in May 2026.

Thesis Invalidation Triggers

Severe manufacturing failures or safety signals leading to FDA clinical holds or product recalls.
Failure to meet the guided FY2026 revenue range of $350M to $370M.
Significant delays in the registrational timelines for NSCLC or endometrial cancer indications.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.